Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPB 101

Next Previous
Drug Profile

OPB 101

Alternative Names: OPB-101

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Outpace Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 27 Jun 2025 Outpace Bio plans phase I trial in Ovarian cancer (Recurrent, Second-line therapy and greater and Late-stage disease) in US (NCT07030907)
  • 16 Jun 2025 Phase-I clinical trials in Ovarian cancer in USA (Parenteral) (NCT07030907)
  • 08 Nov 2024 Pharmacodynamics data from the preclinical studies in Ovarian cancer released by Outpace Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top